ImmuCell Corporation ICCC
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +66.83%
- 1 year
- +68.47%
- Open
- 10.25
- Prev close
- 10.54
- Mkt cap
- 93.18M
- Vol
- 11.02K
- Avg vol
- 18.05K
- EPS
- 0.07
- P/E
- 146.57
- Div yield
- 0.00%
More statistics
- Low
- 9.98
- High
- 10.36
- Forward P/E
- -42.82
- Beta
- 0.57
- Short ratio
- 0.23
- Inst. own
- 14.51%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.93
- 200-d avg
- 4.28
- 1y target
- 0.00
Key statistics
- Market cap
- 41.97M
- Enterprise value
- 42.71M
- Trailing P/E
- 0.00
- Forward P/E
- -42.82
- PEG ratio
- 0.00
- Price / sales
- 1.81
- Price / book
- 1.46
- EPS (TTM)
- -0.49
- Beta
- 0.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -17.44%
- Revenue (TTM)
- 23.22M
- Revenue growth
- 54.90%
- Free cash flow
- 522.36K
- Total cash
- 1.32M
- Total debt
- 15.84M
- Return on equity
- -16.10%
- Shares outstanding
- 8.91M
- Short % of float
- 0.06%
- 50-day average
- 3.93
- 200-day average
- 4.28
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.09 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.20 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -0.06 | — | — |
| Feb 27, 2024 | Dec 1, 2023 | 0.00 | -0.15 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -0.12 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -0.18 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 13, 2020 | Aegis Capital | init | — | Buy |
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immucell.com
News
- ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?
- ImmuCell Reports Q3 Preliminary Sales Of $8M, Up 46% YoY
- ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results
- ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2
- ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?
- ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript
- ImmuCell Reports Q2 2026 Results: Full Earnings Call Transcript
- ImmuCell Q2 Earnings Call Highlights
- ImmuCell Q2 EPS $0.20 Up From $0.06 YoY, Sales $7.186M Up From $6.445M YoY
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
Your note
Sign in to keep a note on ICCC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cresset Asset Management, LLC | 2.96% | 264,002 | 1.24M | Sep 29, 2024 |
| Vanguard Group Inc | 2.53% | 225,595 | 1.06M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.68% | 149,489 | 704.09K | Sep 29, 2024 |
| Bleichroeder LP | 1.14% | 101,594 | 478.51K | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 0.82% | 72,682 | 342.33K | Sep 29, 2024 |
| Morgan Stanley | 0.71% | 63,516 | 299.16K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.78% | 158,957 | 748.69K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.75% | 66,638 | 313.86K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.33% | 29,102 | 137.07K | Oct 30, 2024 |
| DFA U.S. Small Cap Value Series | 0.32% | 28,578 | 134.60K | Jul 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 13,747 | 64.75K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.15% | 13,127 | 61.83K | Oct 30, 2024 |